Eli Lilly Collaborates With OpenAI To Use Generative AI To Invent Novel Antimicrobials
(RTTNews) - Eli Lilly and Co. (LLY) announced Tuesday a collaboration with OpenAI that will allow Lilly to leverage OpenAI's generative AI to invent novel antimicrobials to treat drug-resistant pathogens.
Antimicrobial resistance (AMR) is one of the top public health and development threats across the global health landscape. The misuse and overuse of antimicrobials in humans, animals and plants are the main drivers in the development of drug-resistant pathogens, magnifying this threat to global health.
This collaboration with OpenAI supports Lilly's earlier commitment to fighting drug-resistant pathogens through its Social Impact Venture Capital Portfolio.
In 2020, the portfolio committed $100 million to the AMR Action Fund, aiming to provide patients with two to four new antibiotics by 2030 and contribute the next line of defense against multi-drug-resistant pathogens.
In April 2023, the AMR Action Fund announced its latest investments in biotech companies targeting a range of infections.
Eli Lilly Q2 Results Top Estimates; Boosts FY24 Outlook
Eli Lilly Again Boosts FY24 Outlook - Update
Eli Lilly CFO Anat Ashkenazi Resigns
Lilly Says Phase 3 Trials Of Once-weekly Insulin In Type 2 Diabetes Meets Primary Endpoint
Eli Lilly Boosts FY24 Outlook - Update
Eli Lilly Q4 Results Top Estimates
Eli Lilly Guides FY24 Revenues Above Estimates - Update
